OINDP specialist CDMO Kenox Pharmaceuticals has announced the appointment of Julianne Berry as VP of R&D and Manufacturing. Berry was most recently VP, Respiratory Product Development at Odin Pharmaceuticals and has extensive experience in the development of inhaled and nasal products, including 23 years at Merck. She also worked in respiratory product development at Lupin and was Senior Director of Respiratory Research and Development at Glenmark prior to joining Odin.
In January 2025, Kenox announced that it was adding clinical-scale GMP manufacturing capabilities for inhaled and nasal products. Recently, the company said that it had signed an agreement with Strides Pharma Global for development of intranasal products.
Berry commented, “I am thrilled to join the highly experienced and creative Kenox team committed to accelerating the development of an innovative pipeline of inhaled, intranasal, and ophthalmic products. I’m excited to help bring these life-changing therapies to the clinic faster and more efficiently so patients can access them as quickly as possible.”
Read the Kenox Pharmaceuticals announcement
